USOR 24046 - Ph3 study of T-DXd in patients with HER2-expressing endometrial cancer

An Open-Label, Sponsor-Blinded, Randomized, Controlled, Multicenter, Phase III Study of Trastuzumab Deruxtecan (T-DXd) Plus Rilvegostomig or Pembrolizumab vs Chemotherapy Plus Pembrolizumab as FirstLine Therapy of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer

Disease Types: Endometrial

Available at: Arlington Heights, Chicago Resurrection, Niles